JP6283680B2 - サキナビル−ｎｏの免疫調節効果 - Google Patents

サキナビル−ｎｏの免疫調節効果 Download PDF

Info

Publication number
JP6283680B2
JP6283680B2 JP2015542309A JP2015542309A JP6283680B2 JP 6283680 B2 JP6283680 B2 JP 6283680B2 JP 2015542309 A JP2015542309 A JP 2015542309A JP 2015542309 A JP2015542309 A JP 2015542309A JP 6283680 B2 JP6283680 B2 JP 6283680B2
Authority
JP
Japan
Prior art keywords
saq
cells
mice
effect
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015542309A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015537023A (ja
JP2015537023A5 (enExample
Inventor
フェルディナンド ニコレッティ、
フェルディナンド ニコレッティ、
Original Assignee
オンコノックス アーペーエス
オンコノックス アーペーエス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オンコノックス アーペーエス, オンコノックス アーペーエス filed Critical オンコノックス アーペーエス
Publication of JP2015537023A publication Critical patent/JP2015537023A/ja
Publication of JP2015537023A5 publication Critical patent/JP2015537023A5/ja
Application granted granted Critical
Publication of JP6283680B2 publication Critical patent/JP6283680B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2015542309A 2012-11-20 2013-11-20 サキナビル−ｎｏの免疫調節効果 Expired - Fee Related JP6283680B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261728330P 2012-11-20 2012-11-20
US61/728,330 2012-11-20
PCT/EP2013/074264 WO2014079868A1 (en) 2012-11-20 2013-11-20 Saquinavir-no for immunomodulation

Publications (3)

Publication Number Publication Date
JP2015537023A JP2015537023A (ja) 2015-12-24
JP2015537023A5 JP2015537023A5 (enExample) 2017-01-05
JP6283680B2 true JP6283680B2 (ja) 2018-02-21

Family

ID=49759262

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015542309A Expired - Fee Related JP6283680B2 (ja) 2012-11-20 2013-11-20 サキナビル−ｎｏの免疫調節効果

Country Status (11)

Country Link
US (1) US20150283127A1 (enExample)
EP (1) EP2922545B1 (enExample)
JP (1) JP6283680B2 (enExample)
KR (1) KR20150084862A (enExample)
CN (1) CN104822379B (enExample)
AU (1) AU2013349804A1 (enExample)
BR (1) BR112015011299A2 (enExample)
CA (1) CA2891771A1 (enExample)
IL (1) IL238866A0 (enExample)
MX (1) MX2015006249A (enExample)
WO (1) WO2014079868A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104127858A (zh) * 2014-07-26 2014-11-05 滨州医学院 甲磺酸沙奎拉韦在制备预防或治疗内毒素血症和脓毒症的药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6605289B1 (en) * 1998-06-09 2003-08-12 Embro Research Company, Llc. Method and composition for the treatment of epidermal irritations and infections
FR2779653B1 (fr) * 1998-06-11 2002-12-20 Inst Nat Sante Rech Med Utilisation de composes modulateurs du proteasome en therapie
AU2002346594A1 (en) * 2001-12-14 2003-06-30 Cedars-Sinai Medical Center Use of hiv-1 protease inhibitors and their derivatives in the treatment of inflammation
PL2306995T3 (pl) * 2008-08-01 2014-12-31 Onconox Aps Właściwości przeciwnowotworowe inhibitorów proteazy zmodyfikowanych NO
CN103347539A (zh) * 2010-12-22 2013-10-09 范斯坦医药研究院 使用hiv蛋白酶抑制剂治疗系统性红斑狼疮的方法

Also Published As

Publication number Publication date
AU2013349804A1 (en) 2015-06-04
CA2891771A1 (en) 2014-05-30
IL238866A0 (en) 2015-06-30
US20150283127A1 (en) 2015-10-08
CN104822379B (zh) 2017-08-25
CN104822379A (zh) 2015-08-05
MX2015006249A (es) 2015-12-03
EP2922545A1 (en) 2015-09-30
HK1212895A1 (zh) 2016-06-24
JP2015537023A (ja) 2015-12-24
BR112015011299A2 (pt) 2017-07-11
EP2922545B1 (en) 2016-09-21
KR20150084862A (ko) 2015-07-22
WO2014079868A1 (en) 2014-05-30

Similar Documents

Publication Publication Date Title
Zou et al. Baicalin attenuates TNBS-induced colitis in rats by modulating the Th17/Treg paradigm
Watanabe et al. Danger signaling through the inflammasome acts as a master switch between tolerance and sensitization
Hou et al. Rapamycin ameliorates experimental autoimmune encephalomyelitis by suppressing the mTOR-STAT3 pathway
Buckley et al. Cyclophosphamide therapy of peripheral uveitis
Dagan et al. When uncommon and common coalesce: adult onset Still’s disease associated with breast augmentation as part of autoimmune syndrome induced by adjuvants (ASIA)
WO2012056344A1 (es) Uso de una composición en base a espironolactona, que presenta una acción inhibitoria de la activación de linfocitos t útil para prevenir y/o tratar esclerosis múltiple
Bodar et al. Complete remission of severe idiopathic cold urticaria on interleukin-1 receptor antagonist (anakinra)
KR101432246B1 (ko) 메포민을 포함하는 자가면역질환 예방 및 치료용 조성물
Zhang et al. Paeoniflorin mitigates PBC-induced liver fibrosis by repressing NLRP3 formation
Shi et al. Compound Danshen Dripping Pill effectively alleviates cGAS-STING-triggered diseases by disrupting STING-TBK1 interaction
JP6283680B2 (ja) サキナビル−ｎｏの免疫調節効果
Meczker et al. 5-ASA induces mild acute pancreatitis. Case report and review of the literature
Petković et al. Saquinavir-NO inhibits S6 kinase activity, impairs secretion of the encephalytogenic cytokines interleukin-17 and interferon-gamma and ameliorates experimental autoimmune encephalomyelitis
Keino et al. Therapeutic effect of the potent IL-12/IL-23 inhibitor STA-5326 on experimental autoimmune uveoretinitis
JP2016153374A (ja) 炎症性疾患を治療又は予防するための医薬組成物
Becker et al. Plasmapheresis in the treatment of glomerulonephritis
Li et al. Curcumin improves experimentally induced colitis in mice by regulating follicular helper T cells and follicular regulatory T cells by inhibiting interleukin-21.
JP6708376B2 (ja) ＩＦＮ−γ及び／又はＩＬ−１７の産生抑制剤、並びにＴｈ１細胞及び／又はＴｈ１７細胞の分化抑制剤
Sabbatani et al. Case report: secondary syphilis presenting with acute severe hepatic involvement in a patient with undiagnosed HIV disease
JPWO2020206299A5 (enExample)
Spadaro et al. Methotrexate effect on anti-cyclic citrullinated peptide antibody levels in rheumatoid arthritis
HK1212895B (en) Saquinavir-no for immunomodulation
WO2022126869A1 (zh) 孕激素在治疗细胞因子释放综合征中的应用
KR20220140562A (ko) 염증성 질환의 치료를 위한 신규 의약
Glatigny et al. Treatment of collagen‐induced arthritis by Natura‐α via regulation of Th‐1/Th‐17 responses

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170808

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171108

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180109

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180129

R150 Certificate of patent or registration of utility model

Ref document number: 6283680

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees